Leerink Partnrs Has Pessimistic Outlook of BMRN Q3 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Wednesday, October 8th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($0.34) for the quarter, down from their prior estimate of $0.78. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $2.67 EPS, Q3 2026 earnings at $0.89 EPS, Q4 2026 earnings at $0.91 EPS, FY2026 earnings at $3.54 EPS and FY2027 earnings at $5.14 EPS.

Several other analysts have also recently commented on BMRN. Wedbush reiterated an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. Raymond James Financial initiated coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 price objective for the company. Wolfe Research set a $95.00 target price on shares of BioMarin Pharmaceutical and gave the stock an “outperform” rating in a report on Tuesday, July 15th. UBS Group lifted their price target on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, Guggenheim upped their price objective on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Thirteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.26.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ:BMRN opened at $52.47 on Monday. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $10.07 billion, a P/E ratio of 15.57, a P/E/G ratio of 0.73 and a beta of 0.33. The business has a 50-day moving average price of $56.02 and a two-hundred day moving average price of $57.82. BioMarin Pharmaceutical has a 1-year low of $51.56 and a 1-year high of $73.51.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Exchange Traded Concepts LLC boosted its position in BioMarin Pharmaceutical by 16.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 25,166 shares of the biotechnology company’s stock worth $1,363,000 after acquiring an additional 3,549 shares during the last quarter. Kaufman Rossin Wealth LLC acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at approximately $247,000. Brighton Jones LLC lifted its position in shares of BioMarin Pharmaceutical by 27.0% in the third quarter. Brighton Jones LLC now owns 26,000 shares of the biotechnology company’s stock worth $1,408,000 after purchasing an additional 5,520 shares in the last quarter. Lineweaver Wealth Advisors LLC acquired a new position in BioMarin Pharmaceutical during the third quarter worth $289,000. Finally, Woodstock Corp bought a new position in BioMarin Pharmaceutical in the third quarter valued at $443,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.